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The RET oncogene is becoming a target of increasingly broad interest in thoracic malig-nancies, from papillary thyroid carcinomas to medullar thyroid cancers, to lung adeno-
carcinomas, and now to small-cell lung cancers. In this issue of the Journal of Thoracic 
Oncology, Dabir et al. identify an activating somatic mutation in the RET oncogene in a 
small-cell lung cancer, and demonstrate that overexpression of either wild-type or mutant 
RET in small-cell lung cancer cell lines increases cell proliferation, activates mitogenic 
pathways, and confers increased reactivity to RET tyrosine kinase inhibitors. While these 
several thoracic tumor types may share an oncogene in common, the mechanisms resulting 
in oncogenic activation and the implications for therapy may be quite distinct.
RET oncogene rearrangement in papillary thyroid cancer was the first recurrent tyro-
sine kinase gene fusion identified in a solid tumor.1 Oncogenic RET gene rearrangements, 
including inversions, intrachromosomal rearrangements, and interchromosomal transloca-
tions, occur in approximately 20% of the sporadic papillary thyroid cancers and 60 to 80% 
of the papillary thyroid cancers induced by radiation exposure. These mutations result in 
growth promotion through constitutive activation of the mitogen-activated protein kinase 
signaling pathway.
Biologically and clinically, of course, papillary thyroid cancers are a world away 
from small-cell lung cancers: the former being indolent and frequently localized tumors 
with an overall 5-year survival rate of 97% to 98%;2,3 the latter being exceptionally aggres-
sive and rapidly metastatic cancers with a 5-year survival rate of 1% to 2%. Major inter-
est in the role of RET as a driver oncogene in lung cancer derived from the identification 
and characterization of RET-containing fusion oncogenes in approximately 2% of lung 
adenocarcinomas, a discovery made concurrently by four independent research groups.4–7 
RET fusion-positive lung adenocarcinoma is a striking example of our current potential 
for exceptionally rapid translation between novel target discovery (2012) and dramatic 
clinical validation (2013).8
The RET tyrosine kinase receptor is required for normal neuroendocrine development. 
Among other neural crest defects, RET-deficient mice demonstrate a failure of maturation 
throughout the sympathetic nervous system.9 In humans, germline missense mutations in 
RET are associated with multiple endocrine neoplasia type 2 (MEN2) syndromes, MEN2A, 
MEN2B, and familial medullary thyroid cancer (MTC).10 The MEN2 syndromes are famil-
ial clusters of tumors of neuroendocrine cancers, including medullary thyroid carcinoma 
and pheochromocytoma. In MEN2A, these tumors are found together with parathyroid 
hyperplasia or adenoma; in MEN2B additional tumors include mucosal and gastrointestinal 
ganglioneuromas. The MEN2 syndromes can be associated with a variety of other neuroen-
docrine cancers, including both pulmonary and extrapulmonary carcinoids.
Dabir et al. extend the spectrum of RET mutant tumors to include another neu-
roendocrine tumor type, small-cell lung cancer, identifying a RET M918T mutation in 
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a metastatic small-cell lung cancer. M918T is the mutation 
most strongly associated with MEN2B syndrome, and is 
also found in approximately 50% of the sporadic medul-
lary thyroid carcinomas. Notably, the M918T mutation is 
one of the most highly transforming RET mutations in vitro 
and leads to a more severe clinical MEN2B phenotype than 
the next most common mutation, A883F.11 It is interest-
ing that the M918T was identified in what is arguably the 
most aggressive neuroendocrine tumor type, small-cell lung 
cancer.
This report is not the first demonstration of RET muta-
tions in small-cell lung cancers. Futami et al.12 identified 
mutations in exon 11 of RET in two small-cell lung cancer 
cell lines, and demonstrated that these were not present in 
germline DNA of the patients from whom these were derived. 
Overall, however, RET mutations in small-cell lung cancer 
are clearly rare. Mulligan et al. looked specifically for RET 
mutations in a panel of 54 small-cell lung cancers and found 
none.13 Two recent relatively comprehensive small-cell lung 
cancer genomic analyses, including a total of more than 100 
cancers, revealed only three examples of RET mutations, 
and at least two of these are of questionable significance.14,15 
Neither of these studies identified RET as a statistically sig-
nificant mutated gene in small-cell lung cancer.
The fact that these mutations are rare does not detract 
from the potential importance of finding such a targetable 
driver for the patient with that particular cancer. The genome 
studies of small-cell lung cancer to date have been biologically 
informative, but somewhat disappointing from a therapeutic 
perspective in that the most commonly identified genetic 
alterations in this tumor type are loss of function mutations or 
deletions in tumor suppressor genes, including nearly univer-
sal inactivation of TP53 and RB.14,15 Loss of functional genetic 
alterations do not provide the clear opportunity for rapid clini-
cal translation offered by an activating mutation in a known 
receptor tyrosine kinase. It would be of great interest to treat 
the rare patient with a RET-mutant small-cell lung cancer with 
a targeted inhibitor of RET.
A consequence of extensive genomic characterization 
of major tumor types has been the fragmentation of these 
tumor types into many distinct subsets defined by mutant 
drivers that may be present at low frequencies across widely 
disparate tumor histologies. Detailed genomic studies have 
revealed oncogenic RET gene mutations in multiple tumor 
types, typically at a very low frequency (Fig. 1). Our cancer 
center among several others has approached this problem by 
launching a unified comprehensive next generation sequenc-
ing platform covering a few hundred genes implicated in 
cancer, applied as a clinical test across all tumor types. This 
approach supports the conduct of “basket trials,” early phase 
studies of novel targeted therapies specifically in the patients 
whose tumors harbor the putative oncogenic target. One goal 
is to facilitate rapid drug development by focusing on the 
patient populations most likely to benefit from these novel 
agents.
The relative paucity of tumor material for molecular 
and genetic analysis constitutes a primary barrier to prog-
ress in small-cell lung cancer research. This disease has 
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Figure 1.  Reported frequencies of gene alterations in RET across multiple common solid tumor types. Data are derived from 
cBioPortal (www.cbioportal.org). The primary sources of these datasets are from the Cancer Genome Atlas Consortium (TCGA); 
esophagus cancer was not included in TCGA, and data is from the Broad Institute. Data on small-cell lung cancer, also not 
in TCGA, are derived from two genome profiling reports, references 13 (Clinical Lung Cancer Genome Project [CLCGP]) and 
14 (Johns Hopkins University [JHU]). Adeno, adenocarcinoma; SC, small cell; Squ, squamous; ACC, adrenocortical carcinoma; 
pRCC, papillary renal cell carcinoma; GBM, glioblastoma.
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been typically diagnosed by fine-needle aspirate, and pri-
mary tumors are only rarely surgically resected. The genomic 
studies performed to date have been small in scale relative 
to those of the tumor types analyzed by the Cancer Genome 
Atlas consortium—too small to dependably identify recur-
rent genetic alterations in small-cell lung cancer with a 
frequency of less than 5%. Some of the exciting recent prog-
ress in targeted therapy for lung adenocarcinoma has been 
directed at oncogenic drivers (BRAF, ROS1, RET, even ALK) 
well below this threshold. These observations underscore the 
need for substantially broader and deeper characterization of 
potentially targetable genomic alterations in small-cell lung 
cancer. There may be more gold in the hills, but it is going to 
take some digging.
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